Login to Your Account

Lilly’s VC Arm Invests in China’s Cansino Biotech

By Shannon Ellis
Staff Writer

Wednesday, October 2, 2013
SHANGHAI – The venture capital arm of Eli Lilly and Co. plans to invest in a small but rapidly growing biotech company with a strong pipeline to push forward the development of a third-generation whooping cough vaccine.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription